Health Care • Biotechnology: Pharmaceutical Preparations
$41.84 ▲ +0.76
(+1.85%)
MKT CAP: $2.43B • VOL: 1.89M
52W L $38 52W H $60
SUPN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $719.0M | $661.8M | $607.5M |
| YoY Revenue Growth % | +8.6% | +8.9% | — |
| Gross Profit | $644.4M | $583.9M | $267.3M |
| Gross Margin % | 89.6% | 88.2% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$62.3M | $81.7M | -$5.3M |
| Operating Margin % | -8.7% | 12.3% | -0.9% |
| Net Income (GAAP) | -$38.6M | $73.9M | $1.3M |
| EBITDA (Normalized) | -$61.2M | $82.2M | $16.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $47.3M | $172.0M | $111.1M |
| Capital Expenditures (CapEx) | $1.3M | $725.0K | $27.3M |
| Free Cash Flow (FCF) | $46.0M | $171.2M | $83.7M |
| FCF Margin % | 6.4% | 25.9% | 13.8% |
| Return on Invested Capital (ROIC %) | -4.4% | 5.8% | -0.5% |
| Cash & Short-Term Equivalents | $128.4M | $69.3M | $147.1M |
| Total Debt (Short + Long Term) | $175.9M | $149.6M | $313.0M |
| Total Stockholders' Equity | $1.06B | $1.04B | $642.1M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SUPN.